Guardant Health, which makes non-invasive blood-based cancer diagnostics tests, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
The Redwood City, CA-based company was founded in 2013 and booked $67 million in revenue for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol GH. Guardant Health filed confidentially on July 5, 2018. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
